The DOI matches its Crossref record.
Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease
Open accessAbstract
Background Aspirin desensitization followed by high-dose aspirin therapy is routinely performed for patients with aspirin exacerbated respiratory disease (AERD). Little is known about the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the therapeutic benefit of high-dose aspirin therapy. Objective We investigated differences in urinary eicosanoid metabolites and blood eosinophils in subjects with AERD who tolerate and those who fail aspirin desensitization, and also in AERD subjects who were successfully treated with high-dose aspirin therapy. Methods 29 subjects with AERD were stratified into those who tolerated aspirin desensitization (Group I) and those who did not (Group II). Urine was analyzed for eicosanoid metabolites at baseline, during aspirin reactions, and on high-dose aspirin therapy. Blood was analyzed for cell differentials at baseline and on aspirin therapy. Results Basal prostaglandin D2 metabolite (PGD-M) (13.6±2.7 vs. 7.0±0.8 pmol/mg Cr; P<.05), and thromboxane metabolite (TX-M) levels (1.4±0.3 vs. 0.9±0.1 pmol/mg Cr; P<.01) were higher in Group II than in Group I. During aspirin reactions, PGD-M remained unchanged while TX-M (0.7±0.1 pmol/mg Cr; P=.07) tended to decrease in Group I. In contrast, PGD-M rose dramatically in Group II (61.3±19.9 pmol/mg Cr; P<.05), while TX-M did not change. The decrease in FEV1 inversely correlated with basal urinary levels of both LTE4 and PGD-M. Blood eosinophil and basophil levels rose while urinary PGD-M (2.2±0.8 pmol/mg Cr, P<.001) decreased on two months of high-dose aspirin therapy in Group I. Conclusion Failure to tolerate aspirin desensitization in a subset of subjects with AERD is associated with PGD2 overproduction. The increase in blood eosinophils and basophils while on high-dose aspirin therapy may reflect the functional consequences of decreased PGD2 release and the therapeutic benefit of aspirin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chronic Rhinosinusitis with Nasal Polyps and Asthma
Laidlaw, T. M., Mullol, J., Woessner, K. M., Amin, N., & Mannent, L. P. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.063 · Cited by 419
Self-citationDiagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper
Kowalski, M. L., Agache, I., Bavbek, S., Bakirtas, A., Blanca, M., Bochenek, G., Bonini, M., Heffler, E., Klimek, L., Laidlaw, T. M., et al. (2019) · Allergy · doi:10.1111/all.13599 · Cited by 360
Self-citationKato, A., Peters, A. T., Stevens, W. W., Schleimer, R. P., Tan, B. K., & Kern, R. C. (2022) · Allergy · doi:10.1111/all.15074 · Cited by 305
Stevens, W. W., Peters, A. T., Hirsch, A. G., Nordberg, C. M., Schwartz, B. S., Mercer, D. G., Mahdavinia, M., Grammer, L. C., Hulse, K. E., Kern, R. C., et al. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2016.12.027 · Cited by 278
Aspirin-Exacerbated Respiratory Disease
White, A. A., & Stevenson, D. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1712125 · Cited by 258
Metadata
- Authors
- Cahill, K. N., Bensko, J. C., Boyce, J. A., & Laidlaw, T. M.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 135
- Issue
- 1
- Pages
- 245-252
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2140124854
- Cited by
- 231
- References
- 0
- FWCI
- 11.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease. https://app.cochat.ai/papers/10.1016/j.jaci.2014.07.031
- The paper
- Cahill, K. N., Bensko, J. C., Boyce, J. A., & Laidlaw, T. M. (2015). Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2014.07.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.